These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 31938368)

  • 1. Targeting STAT3 restores BRAF inhibitor sensitivity through miR-759-3p in human cutaneous melanoma cells.
    Su Y; Yu Y; He D; Zhang J; Wang Z; Sun P; Chen Z
    Int J Clin Exp Pathol; 2018; 11(5):2550-2560. PubMed ID: 31938368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor.
    Wang X; Qu H; Dong Y; Wang G; Zhen Y; Zhang L
    Cancer Biomark; 2018; 23(1):67-77. PubMed ID: 30010109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal transducer and activator of transcription 3 inhibition enhances vemurafenib sensitivity in colon cancers harboring the BRAF
    Wang K; Li Y; Song N; Che X; Hou K; Xu L; Bai M; Wang Q; Wang Y; Zhou Y; Cao M; Liu Y; Zhang J
    J Cell Biochem; 2019 Apr; 120(4):5315-5325. PubMed ID: 30320916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanoma.
    Grzywa TM; Klicka K; Paskal W; Dudkiewicz J; Wejman J; Pyzlak M; Włodarski PK
    PLoS One; 2020; 15(6):e0234707. PubMed ID: 32555626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma.
    Díaz-Martínez M; Benito-Jardón L; Alonso L; Koetz-Ploch L; Hernando E; Teixidó J
    Cancer Res; 2018 Feb; 78(4):1017-1030. PubMed ID: 29229605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in Melanoma.
    Hüser L; Kokkaleniou MM; Granados K; Dworacek J; Federico A; Vierthaler M; Novak D; Arkhypov I; Hielscher T; Umansky V; Altevogt P; Utikal J
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33327495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways.
    Sun X; Li J; Sun Y; Zhang Y; Dong L; Shen C; Yang L; Yang M; Li Y; Shen G; Tu Y; Tao J
    Oncotarget; 2016 Aug; 7(33):53558-53570. PubMed ID: 27448964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
    Caporali S; Amaro A; Levati L; Alvino E; Lacal PM; Mastroeni S; Ruffini F; Bonmassar L; Antonini Cappellini GC; Felli N; Carè A; Pfeffer U; D'Atri S
    J Exp Clin Cancer Res; 2019 Jun; 38(1):272. PubMed ID: 31227006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B.
    Jiang SL; Wang ZB; Zhu T; Jiang T; Fei JF; Liu C; Luo C; Cheng Y; Liu ZQ
    Front Pharmacol; 2021; 12():720619. PubMed ID: 34512348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.
    Xiao J; Egger ME; McMasters KM; Hao H
    BMC Cancer; 2018 Jun; 18(1):675. PubMed ID: 29929490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF
    Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P
    Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma.
    Jiang CC; Croft A; Tseng HY; Guo ST; Jin L; Hersey P; Zhang XD
    Oncogene; 2014 May; 33(20):2577-88. PubMed ID: 23770856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma.
    Zhao B; Cheng X; Zhou X
    Melanoma Res; 2018 Dec; 28(6):521-526. PubMed ID: 30192303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma.
    Luo M; Wu L; Zhang K; Wang H; Wu S; O'Connell D; Gao T; Zhong H; Yang Y
    Cell Signal; 2018 Jan; 42():30-43. PubMed ID: 28982601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rescue of cell cycle progression in BRAF
    Toress-Collado AX; Nazarian R; Jazirehi AR
    Tumour Biol; 2017 Sep; 39(9):1010428317721620. PubMed ID: 28936920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway.
    Li H; Chen L; Li JJ; Zhou Q; Huang A; Liu WW; Wang K; Gao L; Qi ST; Lu YT
    J Hematol Oncol; 2018 May; 11(1):70. PubMed ID: 29843746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.
    Sinnberg T; Makino E; Krueger MA; Velic A; Macek B; Rothbauer U; Groll N; Pötz O; Czemmel S; Niessner H; Meier F; Ikenberg K; Garbe C; Schittek B
    EBioMedicine; 2016 Jun; 8():132-149. PubMed ID: 27428425
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
    Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.